Creation of novel diagnostic methods and epigenome therapy based on higher-order epigenome analysis in treatment-resistant oral cancer
Project/Area Number |
16K20595
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Surgical dentistry
|
Research Institution | Kumamoto University |
Principal Investigator |
|
Project Period (FY) |
2016-04-01 – 2018-03-31
|
Project Status |
Completed (Fiscal Year 2017)
|
Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2017: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Keywords | 口腔癌 / 治療抵抗性 / 高次エピゲノム / DNAメチル化 / ヒストン修飾 / エピゲノム治療 / エピゲノム / 放射線耐性 / 高悪性 / 高転移 |
Outline of Final Research Achievements |
Oral squamous cell carcinoma (OSCC) has been increased morbidity, and its high malignant potential, including metastasis and therapeutic resistance affects patient survival. Herein, we investigated the higher-order epigemomic alteration in therapeutic resistance of OSCC to develop the novel diagnostic methods and epigenome therapy based on epigenome profile. Bromodomain containing 4 (BRD4) associates with acetylated chromatin and facilitates transcriptional activation. BET inhibitor JQ1 suppressed cell proliferation, migration and invasion in OSCC cell lines, and JQ1 reduced expression levels of matrix metalloproteinase 2 (MMP2), which are associated with cancer metastasis. These results suggest that BRD4 may be a novel therapeutic target in OSCC.
|
Report
(3 results)
Research Products
(15 results)
-
-
-
[Journal Article] FBXW7 expression affects the response to chemoradiotherapy and overall survival among patients with oral squamous cell carcinoma: A single-center retrospective study.2017
Author(s)
Hidetaka Arita, Masashi Nagata, Ryoji Yoshida, Yuichiro Matsuoka1, Akiyuki Hirosue, Kenta Kawahara, Junki Sakata, Hikaru Nakashima, Taku Kojima, Ryo Toya, Ryuji Murakami, Akimitsu Hiraki, Masanori Shinohara and Hideki Nakayama.
-
Journal Title
Tumour Biology
Volume: 39
Issue: 10
Pages: 1-9
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Salivary duct carcinoma treated with cetuximab-based targeted therapy: A case report.2017
Author(s)
Kawahara K, Hiraki A, Yoshida R, Arita H, Matsuoka Y, Yamashita T, Koga K, Nagata M, Hirosue A, Fukuma D, Nakayama H.
-
Journal Title
Molecular and clinical oncology
Volume: 6
Issue: 6
Pages: 886-892
DOI
Related Report
Peer Reviewed
-
-
[Journal Article] Predictive value of the combination of SMAD4 expression and lymphocyte infiltration in malignant transformation of oral leukoplakia.2017
Author(s)
Sakata J, Yoshida R, Matsuoka Y, Nagata M, Hirosue A, Kawahara K, Nakamura T, Nakamoto M, Hirayama M, Takahashi N, Nakashima H, Arita H, Ogi H, Hiraki A, Shinohara M, Nakayama H
-
Journal Title
Cancer medicine
Volume: 6
Issue: 4
Pages: 730-738
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
-
[Presentation] Overexpression of IGFBP3 contributes to radioresistance and a poor prognosis in oral squamous cell carcinoma2017
Author(s)
Junki Sakata, Akiyuki Hirosue, Ryoji Yoshida, Yuichiro Matsuoka, Kenta Kawahara, Tatsuro Yamamoto, Hidetaka Arita, Hikaru Nakashima, Shunsuke Gohara, Sho Kawaguchi, Yuka Nagao, Keisuke Yamana, Hideki Nakayama
Organizer
第76回日本癌学会学術総会
Related Report
-
-
-
-
-
[Presentation] 口腔扁平上皮癌におけるHMGA2の臨床的意義2016
Author(s)
坂田純基, 廣末晃之, 吉田遼司, 永田将士, 松岡祐一郎, 有田英生, 中嶋光, 福間大喜, 尾木秀直, 篠原正徳, 中山秀樹
Organizer
第40回日本頭頸部癌学会
Place of Presentation
大宮ソニックシティ、埼玉
Year and Date
2016-06-09
Related Report